<DOC>
	<DOCNO>NCT02261298</DOCNO>
	<brief_summary>The objective study investigate safety , pharmacokinetics , pharmacology efficacy ONO-4538 administered Korean patient advanced recurrent solid tumor refractory intolerant standard therapy appropriate treatment available .</brief_summary>
	<brief_title>ONO-4538 Phase I Study Patients With Solid Tumor</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Nivolumab</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>The treatment phase complete ONO453813 study The development PD identify principal sub investigator accord RECIST guideline ( version 1.1 ) case unplanned tumor assessment diagnostic image perform treatment phase ONO453813 study . It determine continue treatment appropriate worsen clinical symptom attribute disease progression occur .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>